EUVIMEDEUVIMED entdecken
Kohortenstudie

Recombinant LH supplementation and cumulative live birth rate in overweight/obese women: a retrospective cohort study

Xinrong Zhou, Lianci Ren, Xiang Ma, Yajing Wu, Jie Wang, Chun Yuan, Chunyan Jiang, Wei Wu, Chunxiang Wu, Jin Liu, Jing Wang

Reproductive BioMedicine Online · 2025-12 · 51 (6) · 105076

DOI: 10.1016/j.rbmo.2025.105076 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Reproductive BioMedicine Online, 2025-12. Verfasst von Xinrong Zhou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Clinical Reproductive Medicine, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Overweight, Obesity, Luteinizing Hormone, Fertilization in Vitro. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Jiangsu Provincial Maternal and Child Health Research Project, National Natural Science Foundation of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RESEARCH QUESTION: Does recombinant human LH (rhLH) supplementation improve the cumulative live birth rate (CLBR) in overweight/obese women undergoing IVF? DESIGN: This retrospective cohort study was conducted at the Centre for Clinical Reproductive Medicine of the First Affiliated Hospital of Nanjing Medical University, China. Clinical data of patients who underwent IVF from 2013 to 2021 were analysed. In total, 791 oocyte retrieval cycles were included and categorized into recombinant human FSH (rhFSH)/rhLH and rhFSH alone groups. Propensity score matching (PSM) for potential confounders was performed in a 1:1 ratio. After matching, 130 cycles from each group were included in the final analyses. The primary outcome was CLBR. RESULTS: Baseline characteristics of the two groups were comparable after PSM. The gonadotrophin starting dose [200 (IQR 175-225) IU versus 175 (IQR 150-200) IU, P < 0.001] and the total gonadotrophin dose [1800 (IQR 1581.25-2200) IU versus 1600 (IQR 1350-1925) IU, P < 0.001] were significantly higher in the rhFSH/rhLH group compared with the rhFSH alone group. Patients in the rhFSH/rhLH group had a lower oestradiol concentration on trigger day [12,332.95 (IQR 7547.1-18,036.64) pmol/l versus 15,881.00 (IQR 9616.88-21,487) pmol/l, P = 0.007] and fewer oocytes retrieved [10 (IQR 7-13.75) versus 11 (IQR 9-14), P = 0.029] compared with the rhFSH alone group. There were no significant intergroup differences in the rates of biochemical pregnancy (71.65% versus 67.20%, P = 0.443), clinical pregnancy (61.42% versus 60.80%, P = 0.920), miscarriage (20.51% versus 10.53%, P = 0.088) and live birth (48.82% versus 54.40%, P = 0.375) after first embryo transfer. CLBR was also similar [85/130 (65.38%) versus 94/130 (72.31%), P = 0.228]. Results remained consistent on logistic regression after adjusting for potential confounders such as gonadotrophin starting dose, total gonadotrophin dose, oestradiol concentration on trigger day, and oocyte number retrieved. There were no significant differences in obstetric-perinatal complications. CONCLUSION: In overweight/obese women undergoing IVF, rhFSH supplementation with rhLH did not significantly improve CLBR or pregnancy outcomes compared with rhFSH alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OverweightObesityLuteinizing HormoneFertilization in VitroLive BirthHumansFemaleRetrospective StudiesAdultPregnancyRecombinant ProteinsOvulation InductionBirth RatePregnancy RateFollicle Stimulating Hormone

Stichwörter der Autor:innen

Cumulative live birth rateIVFOvarian stimulationOverweight and obesityRecombinant human LH

Substanzen

Recombinant ProteinsLuteinizing HormoneFollicle Stimulating Hormone

Autor:innen und Institutionen

  • Centre for Clinical Reproductive Medicine, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Centre for Clinical Reproductive Medicine, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Electronic address: sxmaxiang@126.com.
  • Reproductive Centre of Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Clinical Research Institute of First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Centre for Clinical Reproductive Medicine, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Electronic address: wjbonnie@163.com.

Förderung

  • Jiangsu Provincial Maternal and Child Health Research Project
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Project on Maternal and Child Health Talents of Jiangsu Province
  • Bethune Charitable Foundation

Zitieren

APA

Zhou, X., Ren, L., Ma, X., Wu, Y., Wang, J., Yuan, C., Jiang, C., Wu, W., Wu, C., Liu, J., & Wang, J. (2025). Recombinant LH supplementation and cumulative live birth rate in overweight/obese women: a retrospective cohort study. Reproductive BioMedicine Online, 51(6), 105076. https://doi.org/10.1016/j.rbmo.2025.105076

Vancouver

Zhou X, Ren L, Ma X, Wu Y, Wang J, Yuan C, et al. Recombinant LH supplementation and cumulative live birth rate in overweight/obese women: a retrospective cohort study. Reproductive BioMedicine Online. 2025;51(6):105076. doi:10.1016/j.rbmo.2025.105076

BibTeX
@article{Zhou2025,
  author = {Zhou, Xinrong and Ren, Lianci and Ma, Xiang and Wu, Yajing and Wang, Jie and Yuan, Chun and Jiang, Chunyan and Wu, Wei and Wu, Chunxiang and Liu, Jin and Wang, Jing},
  title = {Recombinant LH supplementation and cumulative live birth rate in overweight/obese women: a retrospective cohort study},
  journal = {Reproductive BioMedicine Online},
  year = {2025},
  volume = {51},
  number = {6},
  pages = {105076},
  doi = {10.1016/j.rbmo.2025.105076}
}
Kostenlos starten →